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Withdrawal of pharmacological treatment for heart failure in 
patients with recovered dilated cardiomyopathy (TRED-HF): 
an open-label, pilot, randomised trial
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Gillian Smith, Lucia Venneri, Upasana Tayal, Dominique Auger, William Midwinter, Nicola Whiffin, Ronak Rajani, Jason N Dungu, Antonis Pantazis, 
Stuart A Cook, James S Ware, A John Baksi, Dudley J Pennell, Stuart D Rosen, Martin R Cowie, John G F Cleland, Sanjay K Prasad
Summary
Background Patients with dilated cardiomyopathy whose symptoms and cardiac function have recovered often ask 
whether their medications can be stopped. The safety of withdrawing treatment in this situation is unknown.
Methods We did an open-label, pilot, randomised trial to examine the effect of phased withdrawal of heart failure 
medications in patients with previous dilated cardiomyopathy who were now asymptomatic, whose left ventricular 
ejection fraction (LVEF) had improved from less than 40% to 50% or greater, whose left ventricular end-diastolic 
volume (LVEDV) had normalised, and who had an N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) 
concentration less than 250 ng/L. Patients were recruited from a network of hospitals in the UK, assessed at one 
centre (Royal Brompton and Harefield NHS Foundation Trust, London, UK), and randomly assigned (1:1) to phased 
withdrawal or continuation of treatment. After 6 months, patients in the continued treatment group had treatment 
withdrawn by the same method. The primary endpoint was a relapse of dilated cardiomyopathy within 6 months, 
defined by a reduction in LVEF of more than 10% and to less than 50%, an increase in LVEDV by more than 10% and 
to higher than the normal range, a two-fold rise in NT-pro-BNP concentration and to more than 400 ng/L, or clinical 
evidence of heart failure, at which point treatments were re-established. The primary analysis was by intention to 
treat. This trial is registered with ClinicalTrials.gov, number NCT02859311.
Findings Between April 21, 2016, and Aug 22, 2017, 51 patients were enrolled. 25 were randomly assigned to the 
treatment withdrawal group and 26 to continue treatment. Over the first 6 months, 11 (44%) patients randomly 
assigned to treatment withdrawal met the primary endpoint of relapse compared with none of those assigned to 
continue treatment (Kaplan-Meier estimate of event rate 45·7% [95% CI 28·5–67·2]; p=0·0001). After 6 months, 
25 (96%) of 26 patients assigned initially to continue treatment attempted its withdrawal. During the following 
6 months, nine patients met the primary endpoint of relapse (Kaplan-Meier estimate of event rate 36·0% [95% CI 
20·6–57·8]). No deaths were reported in either group and three serious adverse events were reported in the treatment 
withdrawal group: hospital admissions for non-cardiac chest pain, sepsis, and an elective procedure.
Interpretation Many patients deemed to have recovered from dilated cardiomyopathy will relapse following treatment 
withdrawal. Until robust predictors of relapse are defined, treatment should continue indefinitely.
Funding British Heart Foundation, Alexander Jansons Foundation, Royal Brompton Hospital and Imperial College 
London, Imperial College Biomedical Research Centre, Wellcome Trust, and Rosetrees Trust.
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Outcomes for patients with dilated cardiomyopathy vary, 
but for many the disease runs a benign course.1 An 
improvement in left ventricular ejection fraction (LVEF) 
and reduction in left ventricle size is seen in around 40% of 
patients.2 Plasma concentrations of natriuretic peptides 
might also normalise with treatment.3 Such patients are 
typically young with few comorbidities and have a good 
prognosis.3–6 Although some patients with improved 
function remain symptomatic,3 those with the greatest 
improvement are often rendered asymptomatic.7
Following resolution of symptoms and recovery in 
cardiac function, many patients ask whether it is 
necessary to continue lifelong treatment, especially if 
they are having side-effects. Patients are often young and 
reluctant to take medications for many years without 
evidence of continued benefit. Young women are often 
eager to stop treatment before attempting to become 
pregnant. Medications also represent a substantial 
financial burden for patients in some countries. Reducing 
the number of unnecessary medications might also 
improve overall wellbeing of patients.
Whether patients with a previous diagnosis of dilated 
cardiomyopathy and clinical, imaging, and biochemical 
markers of recovered cardiac function benefit from 
continuing treatment indefinitely is unknown. Some 
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patients with these features might have achieved 
permanent recovery and so continued treatment might be 
unnecessary. For others, relapse could occur if treatment 
is withdrawn. There is an absense of prospective data 
investigating treatment withdrawal in patients with 
recovered dilated cardiomyopathy and consequently no 
consensus among experts or clear recommendations in 
guidelines.8 Accordingly, we aimed to do a pilot study to 
examine the effect of treatment withdrawal in patients 
with clinical, imaging, and biochemical evidence of 
recovery from dilated cardiomyopathy.
Methods
Study design and patients
We did an open-label, pilot, randomised trial of phased 
withdrawal of pharmacological treatment for heart 
failure. Investigations were done at a single centre (Royal 
Brompton and Harefield NHS Foundation Trust, London, 
UK). Patients were identified at the trial centre and 
participant identification centres in the UK (Guy’s and 
St Thomas’ NHS Foundation Trust, King’s College 
Hospital NHS Foundation Trust, St George’s NHS 
Foundation Trust, London Northwest NHS Healthcare 
Trust, Epsom and St Helier University Hospitals, 
and Basildon and Thurrock University Hospitals). All 
patients provided written informed consent. The possible 
risk of heart failure and major arrhythmia was discussed. 
The trial was approved by the National Research Ethics 
Committee (16/LO/0065), to whom annual progress 
reports were submitted, and given NHS Permission by 
the Royal Brompton and Harefield NHS Trust after 
review of study documentation and discussion of the 
risks and benefits. The trial was authorised by the 
Medicines and Healthcare Products Regulatory Agency 
and annual development safety update reports were 
provided. The study design was discussed with the 
institutional patient advisory group and representatives 
from patient organ isations and was presented at the 
National Heart Failure Patient Health Care Professional 
Research Forum, receiving positive feedback. A senior 
heart failure expert was appointed as an independent trial 
data monitor, who reviewed study conduct and adverse 
events at scheduled meetings, was informed of serious 
adverse events as they occurred, and had the authority to 
terminate the trial if deemed necessary. Serious adverse 
events were reported to the trial sponsor within 24 h as 
per the protocol. The trial is registered on ClinicalTrials.
gov, number NCT02859311, and the trial protocol is 
included in the appendix.
Inclusion criteria comprised a previous diagnosis of 
dilated cardiomyopathy with LVEF 40% or lower;9 
absence of current symptoms of heart failure; current 
treatment with a loop diuretic, beta-blocker, angiotensin-
converting enzyme (ACE) inhibitor, angiotensin receptor 
blocker (ARB), or mineralocorticoid receptor antagonist 
(MRA), or a combination of these drugs; a current LVEF 
of 50% or greater and a left ventricular end diastolic 
volume indexed to body surface area (LVEDVi) within the 
normal range on cardiovascular magnetic resonance 
(CMR);10 and plasma N-terminal pro-B-type natriuretic 
peptide (NT-pro-BNP) concentration less than 250 ng/L.
Exclusion criteria comprised uncontrolled hypertension 
(clinic blood pressure >160/100 mm Hg); valvular disease 
of moderate or greater severity; estimated glomerular 
filtration rate less than  30 mL/min per 1·73 m²; atrial, 
supra- ventricular, or ventricular arrhythmia requiring 
beta-blockade; pregnancy; angina; and age younger than 
16 years.
Patients were identified from a registry, from clinics at 
the study centre and participant identification centres, 
and from patient organisations. Potential participants 
were invited for a screening visit and underwent 
comprehensive assessment. Imaging was done on a 
3-Tesla scanner (Skyra, Siemens Healthcare; Erlangen, 
Germany) with a standardised protocol including late 
gadolinium enhancement imaging, T1 and extracellular 
volume (ECV) mapping, and strain assessment 
(appendix). Patients with contraindications to MRI 
Research in context
Evidence before this study
We searched PubMed using the terms “recovered ejection 
fraction”, “left ventricular reverse remodelling”, “dilated 
cardiomyopathy”, “therapy withdrawal”, and “treatment 
withdrawal” for randomised or observational studies published 
up to Sept 3, 2018. We did not limit the search to English 
language publications. Previous reports about treatment 
withdrawal in patients with recovered dilated cardiomyopathy 
have been based on retrospective case-note reviews of 
populations with varying levels of recovery. The need for 
continued pharmacological heart failure treatment in patients 
with recovered dilated cardiomyopathy is unclear. Patients 
frequently ask to stop medications and are given conflicting 
medical guidance.
Added value of this study
The results of the TRED-HF trial suggest that around four in 
ten patients with recovered dilated cardiomyopathy will have a 
relapse within 6 months of starting phased withdrawal of 
pharmacological treatment for heart failure.
Implications of all the available evidence
Data from this randomised trial suggest that treatment should 
not usually be withdrawn in patients with recovered dilated 
cardiomyopathy. If a patient wishes to initiate treatment 
withdrawal, cardiac function should be monitored carefully and, 
until more information is available, indefinitely. Further research 
might identify subgroups of patients in whom pharmacological 
treatment for heart failure can be safely withdrawn.
See Online for appendix
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underwent echocardiography with three-dimensional 
assessment of LV volumes (appendix). Blood was drawn 
for plasma NT-pro-BNP (Roche; Basel, Switzerland). 
Patients underwent a symptom-limited treadmill cardio- 
pulmonary exercise test (CPET) with one of three ramp 
protocols (appendix). The protocol was selected on the 
basis of perceived exercise tolerance with the aim of 
completing the test within 8–12 min.11 Patients completed 
the Kansas City Cardiomyopathy Questionnaire (KCCQ) 
and a heart failure symptom assessment questionnaire 
(SAQ; appendix). 
All patients provided informed consent and were 
enrolled if all inclusion criteria and none of the exclusion 
criteria were met. Diagnosis and possible cause of 
dilated cardiomyopathy was confirmed by consultant 
cardiologists with expertise in cardiomyopathy.
To gain insight into potential determinants of relapse, 
genetic sequencing was done with the TruSight Cardio 
Sequencing kit (Illumina, San Diego, CA, USA). Rare 
protein-altering variants were identified and interpreted 
as set out in guidelines. Further details about the 
sequencing are provided in the appendix.12 We focused 
on 12 genes with the most robust evidence for association 
with dilated cardiomyopathy: TTN, DSP, MYH7, LMNA, 
TNNT2, TCAP, SCN5A, BAG3, TNNC1, VCL, TPM1, and 
RBM20.13 A rare variant was defined as an ExAC filtering 
allele frequency less than 8·4 × 10–⁵.14 For TTN, only 
truncating variants that affect exons constitutively 
expressed in the heart were included.15
Randomisation and masking
Patients were randomly assigned, by use of an online 
service, in random permuted blocks to supervised phased 
withdrawal or to continue treatment in a 1:1 allocation 
ratio, stratified by plasma NT-pro-BNP (0–50 ng/L, 
50–125 ng/L, and 125–250 ng/L). This initial randomised 
phase of the study took place over 6 months (figure 1) 
and is outlined below. After 6 months, patients in 
the treatment withdrawal group completed the study 
and those initially assigned to continue treatment 
subsequently had phased withdrawal of treatment in the 
same way over the subsequent 6 months, as part of a 
single-arm crossover phase (figure 1). The study team, 
patients, and clinical teams knew which group the 
patient was assigned to. Patients were provided with 
labelled medications by the hospital pharmacy.
Procedures
Patients randomly assigned to treatment withdrawal 
underwent supervised, step-wise reduction in pharma-
cological treatment over a maximum of 16 weeks 
(figure 1). Patients were reviewed every 2 weeks. Changes 
to medication were made following each review. Clinic 
visits and NT-pro-BNP measurements occurred at least 
Figure 1: Flowchart of TRED-HF study design
ACE=angiotensin converting enzyme. ARB=angiotensin receptor blocker. CMR=cardiovascular magnetic resonance. CPET=cardiopulmonary exercise test. 
KCCQ=Kansas City Cardiomyopathy Questionnaire. MRA=mineralocorticoid receptor antagonist. NT-pro-BNP=N-terminal pro-B-type natriuretic peptide. 
SAQ=symptom assessment questionnaire.
Screening visit
Clinical assessment, symptom questionnaires (KCCQ, SAQ), NT-pro-BNP, CMR, and CPET
16 week follow-up visit
Clinical assessment, NT-pro-BNP measurement, and CMR scan
6 month follow-up visit
Clinical assessment, symptom questionnaires (KCCQ, SAQ), NT-pro-BNP measurement, CMR scan, and CPET
Clinic review at 8 weeks
Clinical assessment and NT-pro-BNP 
measurement
Clinic review every 4 weeks
Clinical assessment and 
NT-pro-BNP measurement
Interim telephone review
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the same protocol
Reduce or stop loop diuretics
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Reduce or stop ACE inhibitors or ARBs
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every 4 weeks during withdrawal. Interim reviews took 
place via telephone if the patient remained asymptomatic 
between visits. Patients initially stopped or reduced the 
dose of loop diuretic, followed by MRA, beta-blocker, and 
finally ACE inhibitor or ARB. If the patient was taking 
the equivalent of, or less than 40 mg of frusemide or 
50 mg of spironolactone, or 25% or less of the maximum 
recommended dose of beta-blocker, ACE inhibitor, or 
ARB, the medication was stopped. If the patient was 
taking a larger dose, this was reduced by 50% in a 
stepwise manner every 2 weeks. Further information 
about the algorithm is included in the appendix. Patients 
in the control group underwent clinical review with 
NT-pro-BNP measurement after 8 weeks.
At 16 weeks, all patients underwent a clinical review that 
included measurement of NT-pro-BNP concentration and 
a CMR scan to ascertain LV volumes and function. Patients 
had a further review at 6 months, which included a CMR 
scan to ascertain LV volumes and function, measurement 
of plasma NT-pro-BNP concentration, and a CPET by use 
of the same protocol as in the baseline visit. Patients 
completed the KCCQ and SAQ. Two patients with existing 
contra indications to MRI and two in whom it became 
contra indicated had three-dimensional echocardiography 
(appendix).
The progress of patients was reviewed at weekly 
meetings by a panel of investigators led by a consultant 
cardiologist. Treatments were re-established if patients 
fulfilled any of the primary endpoint criteria described 
below. Management of patients who did not meet 
the primary endpoint but had adverse events, such as 
episodes of arrhythmia, was discussed by the panel 
with their clinical teams. Decisions about restarting 
treatment following such episodes were made on an 
individual basis. Patients who developed hypertension 
without meeting the primary endpoint were managed 
with indapamide and amlodipine. Those with a blood 
pressure greater than 140/90 mm Hg who had diabetes 
or a 10-year cardiovascular risk of 20% or greater, and all 
those with a blood pressure greater than 160/100 mm Hg 
were started on hypertension treatment. All patients 
had 24 h access to a trial or on-call doctor who was 
available via telephone and provided medical advice and 
follow-up as required. Management of patients at the 
end of the trial was ascertained by their clinical teams in 
line with the protocol.
Outcomes
The primary endpoint was a relapse of dilated 
cardiomyopathy within 6 months, defined by at least one 
of the following: a reduction in LVEF by more than 10% 
and to less than 50%; an increase in LVEDV by more 
than 10% and to higher than the normal range; a two-
fold rise in baseline NT-pro-BNP concentration and to 
more than 400 ng/L; or clinical evidence of heart failure, 
based on signs and symptoms as adjudicated by the 
research team.
Secondary endpoints comprised a composite safety 
endpoint (cardiovascular mortality, major adverse cardio-
vascular events, and unplanned cardiovascular hospital 
admission) and the occurrence of sustained atrial or 
ventricular arrhythmias. Changes between baseline 
and follow-up, in LVEF, LVEDVi, plasma NT-pro-BNP 
concentration, left atrial volume indexed to body surface 
area (LAVi), KCCQ and SAQ scores (with lower scores on 
the KCCQ and higher scores on the SAQ indicating 
greater symptom burden), exercise time and peak oxygen 
consumption on CPET, heart rate, and blood pressure 
were also assessed.
Cardiac volumetric analysis was done by a Core 
Laboratory using CMR Tools (Cardiovascular Imaging 
Solutions, London, UK). Operators were masked to the 
treatment group and stage. Serial scans from each patient 
were analysed by the same operator. NT-pro-BNP was 
measured with the Elecsys immunoassay (Roche; Basel, 
Switzerland) throughout the study.
In May, 2017, the sponsor contacted the independent 
data safety monitor as the primary endpoint rate was 
higher than expected. It was deemed appropriate to 
complete the trial as planned given the absence of 
serious adverse events at this stage and the response to 
treatment re-initiation of those who met the primary 
endpoint.
Statistical analysis
This was a pilot trial designed to assess the advisability and 
feasibility of doing a larger outcome trial, assuming that 
the pilot trial showed that the majority of patients could 
have treatment safely withdrawn without deterioration in 
cardiac function. The pilot trial was not prospectively 
powered to detect a difference in outcome. However, a 
retrospective power calculation showed that the sample 
size had 80% power to detect a difference in outcome, at a 
significance level of 5%, if the incidence of the primary 
endpoint in the intervention group was 26%, assuming 
there were no events in the control group.
Analysis was by intention to treat. Occurrence of the 
primary endpoint in the randomised phase of the study 
is graphically displayed per group with Kaplan-Meier 
survival plots and formally compared with the log-rank 
test. Baseline characteristics are presented according to 
assignment at randomisation and compared with the 
Mann-Whitney test for continuous variables or Fisher’s 
exact test for categorical variables. Data are presented as 
median and IQR or as n (%).
Secondary outcome variables were compared between 
groups in the randomised phase by use of a regression 
model in which the outcome variable at 6 months was the 
response variable and the treatment indicator and outcome 
variable at baseline were explanatory variables (ie, analysis 
of covariance). Skewed variables (eg, NT-pro-BNP) were 
log-transformed to achieve a more normal distribution.
Since the number of patients in each group was small, 
we did a non-randomised analysis comparing secondary 
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outcome variables immediately before treatment with- 
drawal versus 6 months later. This approach compared 
baseline versus 6-month values in patients randomly 
assigned to treatment withdrawal and 6-month versus 
1-year variables for those randomly assigned to the control 
group who underwent treatment withdrawal during the 
crossover phase. Comparisons were made via paired 
t tests. In a prespecified exploratory analysis, we used Cox 
proportional hazards models to investigate whether any 
characteristics predicted occurrence of the primary 
outcome among patients who underwent treatment 
withdrawal, including those in the crossover phase.
A p value less than 0·05 was taken as significant 
throughout. Statistical analyses were done with Stata, 
version 15.1.
Role of the funding source
The British Heart Foundation provided peer review of 
the grant proposal, and had no other role in study 
design, data collection, data analysis, data interpretation, 
or writing of the manuscript. The study received 
additional support from the Alexander Jansons 
Foundation, the Cardiovascular Research Centre and 
National Institute for Health Research Biomedical 
Figure 2: Trial profile
One patient in the treatment withdrawal group who withdrew from the study was excluded from secondary analyses (table 3, table 4) because of absence of follow-up 
data. Therefore, 50 patients completed follow-up in the randomised phase. 49 patients completed follow-up after starting treatment withdrawal in the randomised and 
crossover phases (one patient did not cross over from the continued treatment group to begin treatment withdrawal). AF=atrial fibrillation. CPET=cardiopulmonary 
exercise test. DCM=dilated cardiomyopathy. ITT=intention-to-treat. LVEDVi=left ventricular end-diastolic volume indexed to body surface area. LVEF=left ventricular 
ejection fraction. NSVT=non-sustained ventricular tachycardia. NT-pro-BNP=N-terminal pro-B-type natriuretic peptide. PICs=participant identification centres.
936 patients of all severities from DCM registry 19 referred from PICs 11 contacted research team directly following 
 information from patient groups
83 met inclusion/exclusion criteria and were 
 contactable
50 not screened
12 did not meet inclusion/exclusion criteria
 3 had NT-pro-BNP >250 ThSp ng/L
 5 had LVEF <50%
 2 had LVEDVi higher than the normal range
 1 had short episode of AF during CPET
 1 not randomised because of planned surgery
63 underwent screening visit
51 randomly assigned
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25 assigned to treatment withdrawal group 26 assigned to continued treatment group
24 completed planned follow-up
1 restarted treatment without meeting the 
   primary endpoint for NSVT
25 patients included in ITT primary analysis; 
 24 completed follow-up and included in 
 secondary analyses
26 patients included in ITT primary analysis and in
 secondary analyses 
3 restarted treatment without meeting the 
    primary endpoint for AF or resistant hypertension
26 completed planned follow-up
1 withdrew from study
113 contacted about study
1 did not cross over because of suspected
 paroxysmal AF
25 crossed over to treatment withdrawal
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Research Unit at Royal Brompton Hospital and Imperial 
College London, the Imperial College Biomedical 
Research Centre, the Wellcome Trust, and Rosetrees 
Trust. They had no role in study design, data collection, 
data analysis, data interpretation, or writing of the 
manuscript. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication. 
Results
Between April 21, 2016, and Aug 22, 2017, 51 of 
63 screened patients met all inclusion criteria and none 
of the exclusion criteria and were randomly assigned and 
included in the intention-to-treat analysis (figure 2).
25 patients were randomly assigned to the treatment 
withdrawal group and 26 to the continued treatment 
group. Baseline characteristics were generally similar 
between the two groups (table 1). Among those 
randomly assigned to withdrawal versus those assigned 
to continued treatment, idiopathic dilated cardio-
myopathy (80% vs 58%), previous atrial fibrillation 
(32% vs 15%), and previous unplanned heart failure 
admissions (72% vs 54%) were nominally more 
common. Overall, 34 (67%) patients were men and the 
median age was 55 years (IQR 45–64). The median 
LVEF at initial diagnosis was 25% (IQR 20–33) and the 
Treatment 
withdrawal group 
(n=25)
Continued 
treatment group 
(n=26)
Demographics
Median age, years 54 (46 to 64) 56 (45 to 64)
Men 16 (64%) 18 (69%)
Previous cardiovascular history
Time since initial DCM 
diagnosis, months
63 (36 to 112) 41 (20 to 91)
LVEF at initial diagnosis 28% (20 to 33) 25% (19 to 33)
Absolute improvement in 
LVEF
29% (23 to 36) 30% (25 to 38)
Time since LVEF >50%, 
months
28 (8 to 45) 20 (6 to 44)
Previous unplanned heart 
failure admission
18 (72%) 14 (54%)
Previous excess alcohol 
consumption
8 (32%) 9 (35%)
Previous atrial fibrillation 8 (32%) 4 (15%)
Previous hypertension 3 (12%) 1 (4%)
Diabetes 0 (0%) 1 (4%)
Smoker 0 (0%) 3 (12%)
Cause
Idiopathic 20 (80%) 15 (58%)
Familial 3 (12%) 4 (15%)
Environmental insult 2 (8%) 7 (27%)
Truncating variant in TTN 7 (28%) 4 (15%)
Medications at enrolment
ACE inhibitor or ARB 25 (100%) 26 (100%)
Beta-blocker 21 (84%) 24 (92%)
Mineralocorticoid receptor 
antagonist
12 (48%) 12 (46%)
Loop diuretic 3 (12%) 3 (12%)
Clinical characteristics at enrolment
Body surface area, m² 2·1 (1·7 to 2·3) 2·0 (1·8 to 2·2)
Heart rate, bpm 62 (58 to 74) 70 (60 to 75)
Systolic blood pressure, 
mm Hg
123 (117 to 133) 127 (117 to 134)
Diastolic blood pressure, 
mm Hg
72 (68 to 80) 76 (70 to 80)
Left bundle branch block 3 (12%) 4 (15%)
QRS duration, ms 98 (85 to 108) 94 (88 to 111)
NT-pro-BNP, ng/L 72 (44 to 147) 75 (37 to 133)
(Table 1 continues in next column)
Treatment 
withdrawal group 
(n=25)
Continued 
treatment group 
(n=26)
(Continued from previous column)
CMR variables at enrolment
LVEDVi, mL/m² 86 (66 to 91) 80 (70 to 91)
LVEF 62% (55 to 66) 60% (55 to 61)
LV mass index, g/m² 65 (53 to 76) 69 (62 to 76)
RVEDVi, mL/m²* 79 (66 to 92) 74 (62 to 92)
RVEF* 61% (57 to 64) 60% (54 to 65)
LAVi, mL/m² 41 (33 to 46) 41 (33 to 45)
Presence of late gadolinium 
enhancement*
10 (42) 10 (40)
Native T1 time, ms* 1293 (1253 to 1312) 1283 (1276 to 1328)
Extracellular volume* 25% (24 to 27) 26% (24 to 30)
Global radial strain† 0·30 
(0·23 to 0·38)
0·25 
(0·19 to 0·33)
Global circumferential 
strain†
 –0·16 
(–0·18 to –0·14)
 –0·15 
(–0·16 to –0·12)
Global longitudinal strain*  –0·14 
(–0·15 to –0·13)
 –0·13 
(–0·16 to –0·11)
CPET at enrolment
Peak VO2, mL/kg per min‡ 29 (22 to 32) 26 (22 to 33)
Predicted peak VO2 %‡ 95% (85 to 102) 90% (82 to 106)
Exercise time, s‡ 571 (517 to 642) 577 (538 to 633)
Symptom questionnaire scores
KCCQ, 0–100 97 (94 to 100) 94 (90 to 100)
SAQ, 0–185 11 (5 to 13) 10 (6 to 17)
Data are median (IQR) or n (%). Measurements at baseline screening visits. 
ACE=angiotensin-converting enzyme. ARB=angiotensin receptor blocker. 
bpm=beats per min. CMR=cardiovascular magnetic resonance. 
CPET=cardiopulmonary exercise test. DCM=dilated cardiomyopathy. 
KCCQ=Kansas City Cardiomyopathy Questionnaire. LAVi=left atrial volume 
indexed to body surface area. LV=left ventricular. LVEDVi=left ventricular end 
diastolic volume indexed to body surface area. LVEF=left ventricular ejection 
fraction. NT-pro-BNP=N-terminal pro-B-type natriuretic peptide. RVEDVi=right 
ventricular end diastolic volume indexed to body surface area. RVEF=right 
ventricular ejection fraction. SAQ=symptom assessment questionnaire. 
VO2=oxygen consumption. *Two patients did not undergo CMR at baseline 
because of contraindications. †In addition to the two patients who did not 
undergo CMR, global circumferential and radial strain could not be calculated 
from images available for a third patient. ‡Four patients did not undergo CPET at 
baseline because of musculoskeletal pain or injury.
Table 1: Baseline characteristics of patients
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median time since diagnosis was 57 months (25–98) or 
4·9 years (2·1–8·3) and time since recovery to LVEF 
greater than 50% was 24 months (6–43) or 2·0 years 
(0·7–3·5). At enrolment, all patients were in sinus 
rhythm, the median LVEF was 60% (IQR 55–64) and 
median plasma NT-pro-BNP concentration was 72 ng/L 
(39–135). At enrolment, all patients were taking an ACE 
inhibitor or ARB, 45 (88%) were taking a beta-blocker, 
and 24 (47%) an MRA, but only six (12%) were taking a 
loop diuretic. The six patients not taking a beta-blocker 
had been prescribed one at initial diagnosis but this 
treatment had been stopped before enrolment. Eight 
patients also previously on an MRA had this drug 
discontinued before enrolment. One patient in the 
control group had previous implantation of a cardiac 
resynchronisation device with a defibrillator for primary 
prevention purposes while one patient in the withdrawal 
group had an implantable cardioverter defibrillator in 
situ for secondary prevention purposes.
35 (69%) patients had idiopathic dilated cardio-
myopathy, seven (14%) had familial dilated cardio-
myopathy, and nine (18%) had dilated cardiomyopathy 
secondary to a trigger including previous excess alcohol 
consumption, pregnancy, remote anthracycline admini-
stration, hyperthyroidism, and a previous episode of 
myocarditis. 39 (76%) patients (20 randomly assigned to 
treatment withdrawal and 19 to continue treatment) had 
coronary angiography with no evidence of obstructive 
disease (defined as a stenosis >50% in a major coronary 
artery) and a further four (8%; three randomly assigned to 
treatment withdrawal and one to continue treatment) had 
no evidence of ischaemia on nuclear or magnetic 
resonance stress imaging. Of the remaining eight (16%) 
patients (two randomly assigned to treatment withdrawal 
and six to continue treatment), seven (one randomly 
asssigned to treatment withdrawal and six to continue 
treatment) were younger than 50 years, none had 
evidence of myocardial infarction on imaging, and all 
were considered to have a low probability of coronary 
disease.
11 (22%) of 51 patients had a rare, constitutively 
expressed, truncating variant in TTN that was classified as 
being likely pathogenic (appendix). No other pathogenic 
or likely pathogenic variants were identified in genes 
associated with dilated cardiomyopathy (appendix).
Of the 25 patients initially randomly assigned to 
phased withdrawal of treatment, 11 (44%) met the 
primary endpoint criteria for relapse within 6 months 
compared with none of those assigned to continued 
treatment (figure 3). The Kaplan-Meier estimate of the 
event rate at 6 months in the withdrawal group was 
45·7% (95% CI 28·5–67·2; p=0·0001). One patient 
randomly assigned to withdrawal dropped out of the 
study after enrolment following further discussion with 
their cardiologist. After 6 months, in the single-arm 
crossover phase of the study, 25 (96%) of 26 patients 
initially assigned to continued treatment underwent 
phased withdrawal of treatment, nine of whom met the 
criteria for relapse during the following 6 months 
(Kaplan-Meier estimate of event rate 36·0% [95% CI 
20·6–57·8]; appendix). One patient did not undergo 
treatment withdrawal because of symptoms indicative 
of atrial fibrillation while on treatment during the first 
6 months. Therefore, of the 50 patients who began 
withdrawal, 20 (40%) relapsed during the study period. 
13 (26%) patients relapsed within 16 weeks of beginning 
withdrawal (eight in the treatment withdrawal group 
and five in the crossover phase), all of whom relapsed 
within 8 weeks of taking their last medication. Add-
itionally, four patients restarted heart failure treatment 
without meeting the primary endpoint, including 
two for hypertension refractory to treatment with other 
Figure 3: Kaplan-Meier curve of time to primary endpoint in randomised phase, according to treatment group
One patient dropped out at 7 days. 
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Figure 4: Venn diagram showing components contributing to primary 
endpoint definition
Numbers of patients with each combination of endpoints included. LVEDVi=left 
ventricular end-diastolic volume indexed to body surface area. LVEF=left 
ventricular ejection fraction. NT-pro-BNP=N-terminal pro-B-type natriuretic 
peptide. *Refers to one patient who developed peripheral oedema. 
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Patients Events Hazard ratio 
(95% CI)
p value
Demographics
Age (per 10 years) 50 20 1·6 
(1·0 to 2·4)
0·0309
Women 17 9 1·0 (ref) 0·3190
Men 33 11 0·64 
(0·26 to 1·53)
··
Previous diagnosis and history
Time since initial 
diagnosis, years
50 20 1·1 
(0·71 to 1·7)
0·6587
LVEF at initial 
diagnosis, %
50 20 0·73 
(0·48 to 1·12)
0·148222
Previous atrial fibrillation
No 39 17 1·0 (ref) 0·4897
Yes 11 3 0·66 
(0·19 to 2·26)
··
Previous heart failure admission
No 19 9 1·0 (ref) 0·5109
Yes 31 11 0·74 
(0·31 to 1·79)
··
Causal factors
Cause of DCM
Idiopathic 34 13 1·0 (ref) 0·9487
Familial 7 3 1·2 
(0·4 to 4·3)
··
Environmental 
insult
9 4 1·0 
(0·3 to 3·2)
··
Truncating variant in TTN
No 39 16 1·00 (ref) 0·9765
Yes 11 4 0·98 
(0·33 to 2·94)
··
Medications at baseline
ACE inhibitor or ARB 50 20 NA NA
Not on beta-blocker 
(ref)
6 1 1·0 (ref) 0·1708
Beta-blocker 44 19 3·2 
(0·4 to 24·1)
..
Not on MRA (ref) 26 5 1·0 (ref) 0·0042
MRA 24 15 3·9 
(1·4 to 10·8)
..
Not on loop diuretic 
(ref)
44 16 1·0 (ref) 0·1575
Loop diuretic 6 4 2·4 
(0·8 to 7·1)
..
Number of heart failure medications
≤2 drugs 26 5 1·0 (ref) 0·0040
3 drugs 19 12 3·7 
(1·3 to 10·6)
..
4 drugs 5 3 4·8 
(1·1 to 20·2)
..
Clinical characteristics at enrolment
Heart rate, bpm 50 20 1·2 
(0·8 to 1·9)
0·3120
Systolic blood 
pressure, mm Hg
50 20 0·81 
(0·51 to 1·31)
0·3959
(Table 2 continues in next column)
Patients Events Hazard ratio 
(95% CI) 
p value
(Continued from previous column)
Diastolic blood 
pressure, mm Hg
50 20 0·91 
(0·58 to 1·43)
0·6802
LBBB
No 43 17 1·0 (ref) 0·9042
Yes 7 3 1·1 
(0·3 to 3·7)
··
QRS duration, ms 50 20 1·0 
(0·7 to 1·6)
0·8713
Log NT-pro-BNP, 
ng/L
50 20 1·8 
(1·1 to 2·8)
0·0161
CMR measurements at enrolment
LVEF, % 50 20 0·81 
(0·51 to 1·28)
0·3681
LVEDVi, mL/m²* 50 20 1·1 
(0·7 to 1·8)
0·5838
LAVi, mL/m²* 50 20 1·0 
(0·7 to 1·5)
0·9922
Presence of LGE*
No 28* 11 1·0 (ref) 0·9669
Yes 20 8 0·98 
(0·39 to 2·44)
··
Global radial strain† 47† 19 0·55 
(0·34 to 0·90)
0·0177
Global circumferential 
strain†
47† 19 1·3 
(0·8 to 2·0)
0·3365
Global longitudinal 
strain*
48* 19 1·2 
(0·8 to 1·8)
0·5080
Native T1, ms* 48* 19 0·98 
(0·63 to 1·51)
0·9163
ECV, %* 48* 19 1·2 
(0·80 to 1·79)
0·3933
CPET measurements at enrolment
Peak VO2, 
mL/kg per min‡
47‡ 19 0·63 
(0·39 to 1·04)
0·0703
Predicted peak VO2, 
%‡
47‡ 19 1·1 
(0·7 to 1·7)
0·7162
Data are n, unless otherwise stated. Univariable proportional hazard modelling. 
Timepoint for characteristics taken from the beginning of treatment withdrawal 
(at baseline for those randomly assigned to treatment withdrawal and at the start 
of the single-arm crossover phase for those initially randomly assigned to continue 
treatment). Hazard ratios for continuous variables presented per 1 SD higher, apart 
from age which is presented per 10 years (see appendix). Hazard ratios for 
categorical variables presented with the reference group indicated in the table at 
each point. ACE=angiotensin-converting enzyme. ARB=angiotensin receptor 
blocker. bpm=beats per min. CMR=cardiovascular magnetic resonance. 
CPET=cardiopulmonary exercise test. DCM=dilated cardiomyopathy. 
ECV=extracellular volume. LAVi=left atrial volume indexed to body surface area. 
LBBB=left bundle branch block. LGE=late gadolinium enhancement. LVEDVi=left 
ventricular end diastolic volume indexed to body surface area. LVEF=left 
ventricular ejection fraction. MRA=mineralocorticoid receptor antagonist. NA=not 
available. NT-pro-BNP=N-terminal pro-B-type natriuretic peptide. VO2=oxygen 
consumption. *Two patients did not undergo CMR at start of treatment 
withdrawal because of contraindications. †In addition to the two patients who did 
not undergo CMR, global circumferential and radial strain could not be calculated 
from images available for a third patient. ‡Three patients did not undergo CPET 
at the start of treatment withdrawal because of pain or injury.
Table 2: Hazard ratios for primary outcome by patient characteristics 
among those who underwent treatment withdrawal
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drugs (in the crossover phase), one following an episode 
of atrial fibrillation (in the crossover phase), and 
one following an episode of non-sustained ventricular 
tachycardia (in the treatment withdrawal group; 
figure 2). Therefore, only 25 (50%) of 50 patients 
successfully completed 6 months of follow-up without 
re-initiation of treatment.
Of the 20 patients who met the primary endpoint, 
ten fulfilled more than one criterion for relapse. 12 (60%) 
met the LVEF criterion for relapse, 11 (55%) met the 
LVEDVi criterion, nine (45%) met the NT-pro-BNP 
criterion, and one (5%) developed peripheral oedema 
(figure 4; appendix). Two patients developed shortness of 
breath upon moderate exertion (New York Heart 
Association Class [NYHA] II). Nine of ten patients who 
only met one endpoint criterion also had deterioration in 
at least one other variable that did not reach the 
prespecified threshold. The remaining patient had a 
reduction in LVEF from 52% at baseline to 41% at 
16 weeks.
No deaths, unplanned hospital admissions for heart 
failure, or major adverse cardiovascular events were 
reported in either group. Three serious adverse events 
were reported in the treatment withdrawal group: hospital 
admissions for urinary sepsis, non-cardiac chest pain, 
and an elective procedure for a pre-existing condition. 
Neither patient with an implantable cardioverter-
defibrillator received treatment from the device. Three 
patients developed atrial fibrillation during treatment 
withdrawal, two of whom met the primary endpoint.
All patients who met the primary endpoint 
subsequently restarted treatment. At the next follow-up, 
none of the patients had symptoms of heart failure 
(NYHA class I) and 17 (85%) of 20 had LVEF greater than 
50%. Two patients had improvements in LVEF to 
between 45–50% and one had a reduction in LVEF from 
48% to 43%, prompting intensification of medical 
therapy. In prespecified exploratory analyses to identify 
predictors of the primary endpoint, the following 
baseline characteristics were associated with increased 
risk of relapse in univariable analyses: advancing age 
(p=0·0309), prescription of an MRA before withdrawal 
(p=0·0042), prescription of more than two heart failure 
medications (p=0·0040), increased NT-pro-BNP concen 
tration (p=0·0161), and decreased peak global radial 
strain (p=0·0177; table 2). Patients with lower LVEF at 
original diagnosis and lower peak oxygen consumption 
on exercise tests seemed to have higher rates of relapse 
than those who did not, but these results were not 
significant. Familial dilated cardiomyopathy, presence of 
a truncating variant in TTN, LVEF at enrolment, time 
since original dilated cardiomyopathy diagnosis, and 
presence of late gadolinium enhancement were not 
significantly associated with the primary endpoint. How-
ever, the study was not adequately powered to detect such 
associations. Characteristics of patients who relapsed 
and those who did not are presented in the appendix.
With regard to secondary endpoints between groups 
in the randomised phase, treatment withdrawal was 
associated with a significant decline in LVEF, a 
significant increase in heart rate and diastolic blood 
pressure, and a significant decline in KCCQ score 
(table 3, figure 5). The effect of treatment withdrawal 
on other secondary variables was not significant; 
Mean (SD) in 
continued 
treatment 
group
Mean (SD) in 
treatment 
withdrawal 
group
Estimated mean 
effect of treatment 
withdrawal on 
6-month values 
(95% CI)
p value
LVEF, % (n=50)
Baseline 59 (5) 61 (6) ·· ..
6 months 59 (59) 51 (51) –9·5 (–14·0 to –4·9) 0·0001
LVEDVi, mL/m² (n=49*)
Baseline 80 (13) 79 (14) ·· ..
6 months 81 (81) 84 (84) 4·7 (–1·5 to 11·0) 0·1361
LAVi, mL/m² (n=49*)
Baseline 41 (9) 40 (8) ·· ··
6 months 42 (42) 41 (41) 0·5 (–4·2 to 5·2) 0·8217
Heart rate, bpm (n=50)
Baseline 70 (10) 66 (13) ·· ··
6 months 66 (66) 80 (80) 15·4 (10·0 to 20·9) <0·0001
Systolic blood pressure, mm Hg (n=50)
Baseline 125 (12) 123 (12) ·· ··
6 months 125 (125) 133 (133) 6·6 (–0·1 to 13·4) 0·0547
Diastolic blood pressure, mm Hg (n=50)
Baseline 74 (8) 73 (10) ·· ··
6 months 73 (73) 79 (79) 7·0 (1·9 to 12·1) 0·0083
Log NT-pro-BNP concentration, ng/L (n=50)
Baseline 4·2 (0·8) 4·2 (0·7) ·· ··
6 months 4·3 (4·3) 4·7 (4·7) 0·3 (–0·1 to 0·7) 0·1069
Peak VO2, mL/kg per min (n=43†)
Baseline 27 (7) 28 (7) ·· ··
6 months 27 (27) 26 (26) –1·2 (–3·9 to 1·6) 0·4020
Exercise time, s (n=43†)
Baseline 580 (77) 582 (73) ·· ··
6 months 579 (579) 569 (569) –3·4 (–36·0 to 29·2) 0·8344
KCCQ, 0–100 (n=49‡)
Baseline 93 (8) 96 (4) ·· ··
6 months 94 (94) 91 (91) –5·1 (–9·9 to –0·4) 0·0354
SAQ, 0–100 (n=49‡)
Baseline 2·3 (0·7) 2·1 (0·7) ·· ··
6 months 2·2 (2·2) 2·3 (2·3) 0·3 (–0·1 to 0·6) 0·1483
Measurements at baseline and follow-up in the randomised phase based on assignment at randomisation. 
bpm=beats per min. KCCQ=Kansas City Cardiomyopathy Questionnaire. LAVi=left atrial volume indexed to body 
surface area. LVEDVi=left ventricular end diastolic volume indexed to body surface area. LVEF=left ventricular 
ejection fraction. NT-pro-BNP=N-terminal pro-B-type natriuretic peptide. SAQ=symptom assessment 
questionnaire. VO2=oxygen consumption. *One patient did not have LVEDVi and LAVi data available at follow-up 
because of a new contraindication to cardiovascular magnetic resonance (three-dimensional echocardiography 
used for LVEF follow-up). †Seven patients were unable to complete cardiopulmonary exercise test at either baseline 
and follow-up because of musculoskeletal pain or injury. ‡One patient did not complete questionnaires at 
follow-up. 
Table 3: Secondary outcomes at baseline and at 6-month follow-up by treatment group in the 
randomised phase
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however, we observed non-significant increases in 
LVEDVi, systolic blood pressure, and log NT-pro-BNP 
(table 3). 
In the non-randomised comparison of baseline 
versus follow-up variables for all patients who had 
treatment withdrawal attempted and completed follow-
up (n=49), we observed a significant reduction in LVEF 
and a significant increase in LVEDVi, log NT-pro-BNP, 
heart rate, systolic blood pressure, and diastolic blood 
pressure (table 4). In the analysis of patients who did 
not meet the primary endpoint, we observed a 
significant decline in LVEF and a significant increase in 
heart rate, systolic blood pressure, and diastolic blood 
pressure (table 4).
Of the 50 patients who began treatment withdrawal, 
eight (16%) had a potentially reversible insult, including 
four with previous excess alcohol consumption, two with 
peripartum presentation, one with previous myocarditis, 
and one with hyperthyroidism. Of these patients, three 
(38%) met the primary endpoint, including two with 
previous excess alcohol consumption and one with 
peripartum presentation. Among these eight patients, 
mean LVEF at enrolment was 59% (SD 6·1) and the 
mean LVEF at follow-up was 55% (7·7; mean difference 
–4·6% [95% CI –13·1 to 3·8]; p=0·2333).
16 (32%) patients (nine in the treatment withdrawal 
group, seven in the crossover phase) completed treatment 
withdrawal, remained asymptomatic, and either finished 
the study with LVEF in the normal range or had a 3% or 
lower absolute reduction in LVEF (the expected interstudy 
variability16) or an increase in LVEF. The characteristics 
of these patients are included in the appendix.
Discussion
To the best of our knowledge, this study is the first 
prospective randomised trial to investigate withdrawal of 
heart failure treatment in patients deemed to have 
recovered dilated cardiomyopathy. In this pilot study, 
treatment was withdrawn successfully in only 50% of 
patients, while 40% had a relapse of their dilated 
cardiomyopathy within 6 months. Potentially, more 
patients might have relapsed with a longer duration of 
treatment withdrawal. This finding suggests that, for 
many patients, improvement in cardiac function 
following treatment does not reflect full and sustained 
recovery but rather reflects remission, which requires at 
least some treatment to be maintained. Withdrawal of 
treatment should therefore not be attempted routinely in 
these patients. Further research should aim to identify 
variables that discriminate remission from permanent 
recovery. This research could enable safe withdrawal of 
treatment in some subgroups. Given the speed of 
deterioration, with most patients relapsing within 
8 weeks of their last medication, these findings also 
provide guidance about how to monitor patients if 
treatment withdrawal is attempted, either at the patient’s 
request, because of side-effects, or because the patient is 
considering pregnancy.
Secondary analyses of the randomised groups showed 
worsening KCCQ scores, a substantial reduction in 
LVEF, and non-significant increases in NT-pro-BNP 
and LV volumes. These findings were supported by the 
non-randomised comparison of baseline and follow-up 
variables among patients who had treatment 
withdrawal. Therefore, deterioration in LVEF after 
treatment withdrawal is not simply an imaging artifact 
but reflects disease recurrence. Analyses of patients 
who had withdrawal but did not meet the primary 
endpoint showed that these patients also had an overall 
reduction in LVEF. Our data also show that deterioration 
in LVEF often predated a rise in natriuretic peptides. 
Reproducible imaging, such as MRI, therefore appears 
to be important if withdrawal is considered under 
certain circumstances.
Figure 5: Change in secondary endpoint variables between baseline and follow-up in the randomised phase 
of the study, based on treatment group
Each circle represents one patient. bpm=beats per min. DCM=dilated cardiomyopathy. LVEDVi=left ventricular 
end-diastolic volume indexed to body surface area. LVEF=left ventricular ejection fraction. NT-pro-BNP=N-terminal 
pro-B-type natriuretic peptide.
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Patient safety was a priority. To identify those with 
the greatest degree of recovery, we only included 
asymptomatic patients with normal LV volumes and 
LVEF greater than 50% and excluded patients with 
clearly elevated plasma concentrations of NT-pro-BNP. 
Participants were monitored closely and treatment was 
restarted as soon as any criteria for the endpoint 
were met or if there was another reason to resume treat-
ment, such as atrial fibrillation. The absence of major 
adverse cardiovascular events and unplanned hospital 
admissions for heart failure reflects the early detection 
of deterioration and restarting of medications before 
decompensation. It would have been unethical to wait 
until decompensation was clinically overt after detecting 
deteriorating cardiac function before reinstating treat-
ment. We focused on patients with dilated cardio-
myopathy as these patients are most likely to recover. 
Our data should be extrapolated with caution to patients 
with recovered left ventricular function secondary to 
ischaemic heart disease or hypertension. In ischaemic 
heart disease, ACE inhibitors and beta-blockers can be 
given to reduce further coronary events as well as 
morbidity and mortality related to heart failure. The 
same treatment is also given to control blood pressure 
in patients with hypertensive disease. Patients with 
recovered dilated cardiomyopathy also have a low 
prevalence of other comorbidities that might require 
pharmacological therapy, as indicated by our cohort and 
previous studies.3
Previous studies examining treatment withdrawal 
have been done in heterogeneous populations. Early 
studies were done in patients with reduced LVEF and 
symptoms of heart failure, most of whom had ischaemic 
heart disease.17–20 More contemporary studies in patients 
with dilated cardiomyopathy have been retrospective and 
done in poorly characterised populations, providing 
conflicting results.21,22 Our trial therefore provides the 
first prospective information about the risks of 
withdrawing treatment in patients with recovered dilated 
cardiomyopathy.
Moon and colleagues21 retrospectively investigated 
42 patients with dilated cardiomyopathy whose LVEF had 
improved to greater than 40%. Seven patients 
discontinued treatment, five of whom subsequently had 
a reduction in LVEF at a median follow-up of 32 months. 
However, most patients who deteriorated had LVEF less 
than 50% and LV dilatation. Conversely, Amos and 
colleagues22 studied 22 patients with peripartum 
cardiomyopathy whose LVEF had improved to greater 
than 50%. Ten subsequently stopped either an ACE 
inhibitor or beta-blocker and five stopped both 
medications. None of the patients had a deterioration in 
LVEF over a median follow-up of 29 months. Differences 
in outcome might be related to the cause of dilated 
cardiomyopathy, but it is becoming increasingly clear 
that overlap exists between what have traditionally been 
viewed as separate acquired and genetic conditions.23,24 
For example, a common genetic predisposition appears 
to exist for many patients with idiopathic and peripartum 
dilated cardiomyopathy.23 Although identification of a 
trigger might improve the prediction of outcome, triggers 
can occur many years before presentation and their 
significance at the time of diagnosis is often unclear. 
Because of the overlap between causes, the absence of 
data about any subgroup and to produce a sample that 
was representative of the real-world population, we chose 
Overall Primary endpoint met Primary endpoint not met
Patients Estimated mean 
change between 
baseline and 6 months 
(95% CI)
p value Patients Estimated mean change 
between baseline and 
6 months (95% CI)
p value Patients Estimated mean 
change between 
baseline and 
6 months (95% CI)
p value
LVEF, % 49 –6·9 (–9·6 to –4·3) <0·0001 20  –12·0 (–16·6 to –7·4) 0·0001 29  –3·5 (–5·8 to –1·1) 0·0190
LVEDVi, mL/m² 47* 6·5 (3·1 to 9·8) 0·0003 20 11·8 (8·2 to 15·3) <0·0001 27* 2·5 (–2·0 to 7·0) 0·2107
LAVi, mL/m² 47* 2·0 (–0·6 to 4·6) 0·1224 20 6·6 (3·3 to 9·9) 0·0009 27*  –1·4 (–4·5 to 1·7) 0·3702
Heart rate, bpm 49 13·2 (9·3 to 17·1) <0·0001 20 16·4 (9·1 to 23·6) 0·0003 29 11·7 (7·9 to 15·6) <0·0001
Systolic blood pressure, mm Hg 49 8·7 (4·6 to 12·9) 0·0001 20 8·9 (2·3 to 15·4) 0·0101 29 8·7 (3·4 to 13·9) 0·0020
Diastolic blood pressure, mm Hg 49 6·7 (3·2 to 10·1) 0·0003 20 6·4 (1·7 to 11·0) <0·0001 29 6·9 (2·2 to 11·5) 0·0033
Log NT-pro-BNP, ng/L 49 0·3 (0·0 to 0·6) 0·0246 20 0·4 (0·2 to 0·6) 0·0022 29 0·0 (–0·1 to 0·05) 0·4276
VO2 max (mL/kg per min) 41† –0·7 (–2·1 to 0·7) 0·3294 17† –1·5 (–3·5 to 0·4) 0·1476 24† 0·0 (–1·9 to 2·0) 0·9737
Exercise time (s) 41† –0·6 (–14·9 to 13·8) 0·9376 17† –19·7 (–40·9 to 1·5) 0·0873 24† 12·0 (–4·4 to 28·3) 0·1646
KCCQ, 0–100 49 –2·2 (–4·7 to 0·3) 0·0777 20  –3·9 (–7·7 to –0·11) 0·0582 29  –1·2 (–4·2 to 1·8) 0·4480
SAQ, 0–100 49 0·1 (–0·1 to 0·3) 0·3782 20 1·5 (–2·9 to 5·9) 0·5110 29 0·77 (–1·9 to 3·4) 0·5754
Measurements taken at the start of treatment withdrawal (at baseline for those randomly assigned to treatment withdrawal and at the start of the single-arm crossover phase for those initially randomly 
assigned to continue treatment) and follow-up. A maximum of 49 patients completed follow-up. bpm=beats per min. KCCQ=Kansas City Cardiomyopathy Questionnaire. LAVi=left atrial volume indexed to body 
surface area. LVEDVi=left ventricular end diastolic volume indexed to body surface area. LVEF=left ventricular ejection fraction. NT-pro-BNP=N-terminal pro-B-type natriuretic peptide. SAQ=symptom 
assessment questionnaire. VO2 max=maximum oxygen consumption. *Two patients had absent LVEDVi and LAVi at follow-up because of new contraindication to cardiovascular magnetic resonance; 
three-dimensional echocardiography used for LVEF follow-up. †Eight patients were unable to complete the cardiopulmonary exercise test because of musculoskeletal pain or injury.
Table 4: Non-randomised comparison of secondary outcomes before and after treatment withdrawal for all patients, according to occurrence of primary endpoint
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to include all causes of dilated cardiomyopathy. Similar 
to registries, most patients in this trial were labelled as 
having idiopathic disease.25 Considering the complexity 
of defining the cause, it is not surprising that we found 
no association between the perceived cause and relapse 
in this trial, although the sample size was not large 
enough to detect more subtle associations.
Being able to distinguish between patients who have 
complete recovery as opposed to remission is an 
important goal. Traditional practice has focused on the 
use of LVEF and LV volumes to grade recovery. However, 
within this small trial these variables were poor at 
predicting relapse. Whether the rate of relapse differs 
according to sex and age is unclear and deserves further 
work. It would be reasonable to believe that patients with 
genetic disease would be at increased risk of relapse. 
However, the relapse rate was not clearly greater in those 
with familial disease or a truncating variant in TTN. 
Previous reports have shown the potential for reverse 
remodelling in patients with a truncating variant in 
TTN,15,26 which is consistent with the high prevalence of a 
truncating variant in TTN in our cohort. Imaging and 
circulating biomarkers offer hope for improving disease 
characterisation. Global radial strain and NT-pro-BNP 
concentration were associated with the risk of relapse in 
exploratory analyses in this small sample. Whether these 
analyses are reproducible and able to reliably distinguish 
between recovery and remission requires further work. 
Identification of multiple characteristics that reflect 
different aspects of myocyte function might be needed.
Although this study is, to our knowledge, the only and 
therefore largest randomised trial investigating treatment 
withdrawal for recovered dilated cardiomyopathy, the 
power to examine the association between baseline 
characteristics and relapse was restricted by the number 
of participants. The study might also have been too small 
to identify differences in variables such as NT-pro-BNP, 
which appeared to lag behind the reduction in LVEF. 
Although there were differences in some baseline 
characteristics between groups, these were small in 
absolute numbers and none of these variables was 
associated with the primary outcome. The single-arm 
crossover phase adds support for a consistent effect size 
across the entire population. The study was done in a 
single centre. Although some single-centre studies might 
be susceptible to selection bias, patients in this study 
were recruited from referral sites covering a large, diverse 
population. The baseline characteristics suggest that the 
cohort encompassed the heterogeneity of patients with 
dilated cardiomyopathy. A minimum time with LV 
dysfunction before recovery was not specified. However, 
diagnosis of dilated cardiomyopathy was confirmed by 
experienced clinicians and fulfilled diagnostic criteria.
Although imaging and laboratory investigations were 
masked to the assigned group to minimise bias in 
objective measures, patients and clinicians knew to which 
group patients were assigned. Patients might have been 
biased in favour of treatment withdrawal and attributed 
side-effects to medications they did not wish to take or 
denied the presence of mild symptoms. It is also possible 
that treatment withdrawal provoked anxiety. These 
possibilities should be considered when inter- preting the 
patient-reported deterioration in symptoms. Patients in 
the treatment withdrawal group also underwent more 
frequent follow-up than did those in the continued 
treatment group. Although this aspect of the study design 
could be a source of bias, only two of 20 events were 
detected, without development of symptoms, at visits 
before 16 weeks. We attempted to withdraw all treatment 
for heart failure. Many patients had already stopped 
diuretics. No patients were taking angiotensin receptor-
neprilysin inhibitors as almost all were diagnosed before 
introduction of these drugs and showed favourable 
response to previous conventional treatment.27
The rise in heart rate associated with treatment with-
drawal, which was most marked in those who relapsed, 
suggests that the withdrawal of beta-blockers might be an 
important factor. However, one patient not on a beta-blocker 
at baseline relapsed following treatment withdrawal. Heart 
rate is closely linked to prognosis in patients with heart 
failure and sinus rhythm.28,29 Whether the ongoing benefit 
of beta-blockers in this population is solely related to heart 
rate suppression deserves further consideration. Future 
work should explore which component of treatment is most 
important in preventing relapse. The impact of a change in 
cardiac function following treatment withdrawal on future 
compliance with medication is another worthwhile topic.
In conclusion, in this pilot study, withdrawal of 
pharmacological heart failure treatment in patients with 
recovered dilated cardiomyopathy was associated with 
relapse in 40% of cases. This finding suggests that 
complete withdrawal of treatment should not usually be 
attempted in such patients. Future work could identify 
patient subgroups who have permanent recovery of 
myocardial function for whom withdrawal is safe or for 
whom only some medications need to be continued in 
the long term.
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